DiaMedica Therapeutics Valuation
| DMAC Stock | USD 4.98 0.16 3.11% |
At this time, the firm appears to be overvalued. DiaMedica Therapeutics shows a prevailing Real Value of $4.37 per share. The current price of the firm is $4.98. Our model computes the value of DiaMedica Therapeutics from reviewing the firm fundamentals such as Shares Owned By Insiders of 26.12 %, current valuation of 167.47 M, and Shares Outstanding of 42.86 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting DiaMedica Therapeutics' valuation include:
Overvalued
Today
Please note that DiaMedica Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of DiaMedica Therapeutics is based on 3 months time horizon. Increasing DiaMedica Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since DiaMedica Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DiaMedica Stock. However, DiaMedica Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.98 | Real 4.37 | Target 8.0 | Hype 4.98 | Naive 4.87 |
The real value of DiaMedica Stock, also known as its intrinsic value, is the underlying worth of DiaMedica Therapeutics Company, which is reflected in its stock price. It is based on DiaMedica Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of DiaMedica Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of DiaMedica Therapeutics helps investors to forecast how DiaMedica stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DiaMedica Therapeutics more accurately as focusing exclusively on DiaMedica Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use DiaMedica Therapeutics' intrinsic value based on its ongoing forecasts of DiaMedica Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against DiaMedica Therapeutics' closest peers. If more than one evaluation category is relevant for DiaMedica Therapeutics we suggest using both methods to arrive at a better estimate.
DiaMedica Therapeutics Cash |
|
DiaMedica Valuation Trend
Comparing DiaMedica Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of DiaMedica Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
DiaMedica Therapeutics Total Value Analysis
DiaMedica Therapeutics is currently forecasted to have valuation of 167.47 M with market capitalization of 213.42 M, debt of 340 K, and cash on hands of 38.44 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the DiaMedica Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
167.47 M | 213.42 M | 340 K | 38.44 M |
DiaMedica Therapeutics Asset Utilization
One of the ways to look at asset utilization of DiaMedica is to check how much profit was generated for every dollar of assets it reports. DiaMedica Therapeutics shows a negative utilization of assets of -0.33 percent, losing $0.003318 for each dollar of assets held by the firm. Unsuccessful asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of DiaMedica Therapeutics shows how unproductive it operates for each dollar spent on its assets.DiaMedica Therapeutics Ownership Allocation
DiaMedica Therapeutics holds a total of 42.86 Million outstanding shares. DiaMedica Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.DiaMedica Therapeutics Profitability Analysis
Net Loss for the year was (24.44 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates DiaMedica Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in DiaMedica Therapeutics and how it compares across the competition.
About DiaMedica Therapeutics Valuation
The stock valuation mechanism determines DiaMedica Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of DiaMedica Therapeutics. We calculate exposure to DiaMedica Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of DiaMedica Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -27 K | -25.6 K | |
| Pretax Profit Margin | (10.18) | (10.69) | |
| Operating Profit Margin | (12.17) | (12.78) | |
| Net Loss | (10.32) | (10.84) |
DiaMedica Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 40.4 M |
DiaMedica Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of DiaMedica Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value DiaMedica we look at many different elements of the entity such as DiaMedica's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as DiaMedica Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use DiaMedica Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes DiaMedica Therapeutics' worth.Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |